Protara reports 100% CR at any time in BCG-unresponsive NMIBC; 67% at 12 months

Protara Therapeutics, Inc.

BCG-Unresponsive: 100% CR at any time (5/5), 67% at 12 months (2/3) as of April 16, 2025 cutoff.
BCG-Naïve: 76% CR at any time (16/21), 43% at 12 months (3/7) in Phase 2 ADVANCED-2 trial.
No Grade 3+ treatment-related adverse events; most AEs were Grade 1, transient, and consistent with immunopotentiation.
Company on track to present interim data from ~25 six-month evaluable BCG-Unresponsive patients by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.